HC Wainwright Issues Pessimistic Estimate for VTYX Earnings

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Equities researchers at HC Wainwright cut their FY2029 earnings estimates for shares of Ventyx Biosciences in a research note issued to investors on Thursday, January 8th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($1.57) for the year, down from their prior estimate of ($1.50). HC Wainwright currently has a “Neutral” rating and a $14.00 target price on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share.

Several other research analysts have also issued reports on VTYX. Clear Str lowered Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 7th. Oppenheimer lowered Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research note on Thursday. Lifesci Capital restated a “market perform” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a report on Thursday, January 8th. Wells Fargo & Company reissued an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Finally, Piper Sandler lowered shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price target on the stock. in a research note on Thursday. Eight investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $14.00.

Ventyx Biosciences Trading Up 0.2%

Shares of VTYX opened at $13.84 on Monday. The firm has a market cap of $987.62 million, a PE ratio of -9.23 and a beta of 1.23. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $25.00. The stock has a fifty day moving average price of $9.38 and a 200-day moving average price of $5.40.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Hudson Bay Capital Management LP acquired a new stake in Ventyx Biosciences in the 2nd quarter valued at $34,000. Pallas Capital Advisors LLC purchased a new position in Ventyx Biosciences during the second quarter valued at $38,000. Engineers Gate Manager LP acquired a new stake in shares of Ventyx Biosciences in the second quarter valued at about $42,000. Persistent Asset Partners Ltd purchased a new position in Ventyx Biosciences in the 3rd quarter valued at about $51,000. Finally, Jump Financial LLC acquired a new stake in Ventyx Biosciences in the 2nd quarter worth about $53,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Ventyx Biosciences news, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Nuss sold 12,675 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider owned 489,481 shares in the company, valued at $3,778,793.32. This trade represents a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 18.18% of the stock is currently owned by insiders.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.